Systematic review of the literature informing the systemic lupus erythematosus indicators project: Reproductive health care quality indicators

Arthritis Care and Research

Volumn 63, Issue 1, 2011, Pages 17-30

  ZelL Gillis, Joann ^a   Panopalis, Pantelis ^b   Schmajuk, Gabriela ^c   Ramsey Goldman, Rosalind ^d   Yazdany, Jinoos ^e  

^a DEPARTMENT OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c STANFORD UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CHLOROQUINE PLUS HYDROXYCHLOROQUINE SULFATE PLUS MEPACRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DALTEPARIN; ENOXAPARIN; GLUCOCORTICOID; HEPARIN; IMMUNOGLOBULIN; LEFLUNOMIDE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RO ANTIBODY; THALIDOMIDE;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CHROMOSOME ABERRATION; COMPARATIVE STUDY; CONGENITAL HEART BLOCK; CRANIOFACIAL MALFORMATION; DATA BASE; DATA EXTRACTION; DRUG SAFETY; EMBRYOTOXICITY; EYE TOXICITY; FEASIBILITY STUDY; FETUS MALFORMATION; HEALTH CARE QUALITY; HUMAN; HYPOPLASIA; INFECTION; INTRAUTERINE GROWTH RETARDATION; LABORATORY TEST; LIMB MALFORMATION; LOW BIRTH WEIGHT; LOW DRUG DOSE; METHODOLOGY; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY OUTCOME; PREMATURITY; PRENATAL SCREENING; PROGNOSIS; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENESIS; TREATMENT OUTCOME; VALIDITY; FEMALE; REPRODUCTION; RETROSPECTIVE STUDY; REVIEW; STANDARD;

FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; QUALITY INDICATORS, HEALTH CARE; REPRODUCTIVE MEDICINE; RETROSPECTIVE STUDIES;

EID: 79952231197     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20327     Document Type: Article

References (79)

1. Khanna D, Arnold EL, Pencharz JN, Grossman JM, Traina SB, Lal A, et al. Measuring process of arthritis care: the Arthritis Foundation's quality indicator set for rheumatoid arthritis. Semin Arthritis Rheum 2006;35:211-37. (Pubitemid 43185213)
2. Mikuls TR. Quality of care in gout: from measurement to improvement. Clin Exp Rheumatol 2007;25 Suppl 47:114-9.
3. Mikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT, et al. Quality of care indicators for gout management. Arthritis Rheum 2004;50:937-43. (Pubitemid 38326194)
4. Campbell SM, Braspenning J, Hutchinson A, Marshall MN. Research methods used in developing and applying quality indicators in primary care. BMJ 2003;326:816-9. (Pubitemid 36523598)
5. MacLean CH. Quality indicators for the management of osteoarthritis in vulnerable elders. Ann Intern Med 2001;135:711-21. (Pubitemid 33015484)
6. MacLean CH, Pencharz JN, Saag KG. Quality indicators for the care of osteoarthritis in vulnerable elders. J Am Geriatr Soc 2007;Suppl 2:S383-91. (Pubitemid 47515349)
7. Yazdany J, MacLean CH. Quality of care in the rheumatic diseases: current status and future directions. Curr Opin Rheumatol 2008;20:159-66. (Pubitemid 351339887)
8. Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, et al, and the Systemic Lupus Erythematosus Quality Indicators Project Expert Panels. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum 2009;61: 370-7.
9. Brook RH. The RAND/UCLA appropriateness method. In: Mc-Cormick KA, Moore SR, Siegel RA, editors. Methodology perspectives. Rockville (MD): Public Health Service, US Department of Health and Human Services; 1994. p. 59-70.
10. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum 1999;42:1785-96.
11. Gordon P, Khamashta MA, Rosenthal E, Simpson JM, Sharland G, Brucato A, et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol 2004; 31:2480-7. (Pubitemid 39603101)
12. Brucato A, Doria A, Frassi M, Castellino G, Franceschini F, Faden D, et al. Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus 2002;11:716-21. (Pubitemid 35408076)
13. Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001;44:1832-5. (Pubitemid 32758230)
14. Julkunen H, Kaaja R, Siren MK, Mack C, McCready S, Holthofer H, et al. Immune-mediated congenital heart block (CHB): identifying and counseling patients at risk for having children with CHB. Semin Arthritis Rheum 1998;28:97-106. (Pubitemid 28480894)
15. Lee LA. Transient autoimmunity related to maternal autoantibodies: neonatal lupus. Autoimmun Rev 2005;4:207-13. (Pubitemid 40704704)
16. Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998;31:1658-66. (Pubitemid 28273312)
17. Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003;142:678-83. (Pubitemid 36737172)
18. Izmirly PM, Rivera TL, Buyon JP. Neonatal lupus syndromes. Rheum Dis Clin North Am 2007;33:267-85. (Pubitemid 46710331)
19. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205. (Pubitemid 351183308)
20. Wang Y, Schrieber L, Cohen MG, Furphy L, Webb J, Chivers T, et al. Antiphospholipid antibodies in systemic lupus erythematosus: clinical and laboratory associations in 111 patients. Rheumatol Int 1990;10:75-80. (Pubitemid 20325447)
21. Wilson WA, Gharavi AE, Piette JC. International classification criteria for antiphospholipid syndrome: synopsis of a postconference workshop held at the Ninth International (Tours) aPL Symposium. Lupus 2001;10:457-60. (Pubitemid 32675043)
22. Soubassi L, Haidopoulos D, Sindos M, Pilalis A, Chaniotis D, Diakomanolis E, et al. Pregnancy outcome in women with pre-existing lupus nephritis. J Obstet Gynaecol 2004;24: 630-4. (Pubitemid 39655418)
23. Cortes-Hernandez J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford) 2002;41:643-50. (Pubitemid 34618882)
24. Lima F, Buchanan NM, Khamashta MA, Kerslake S, Hughes GR. Obstetric outcome in systemic lupus erythematosus. Semin Arthritis Rheum 1995;25:184-92. (Pubitemid 26001344)
25. Rubbert A, Pirner K, Wildt L, Kalden JR, Manger B. Pregnancy course and complications in patients with systemic lupus erythematosus. Am J Reprod Immunol 1992;28:205-7. (Pubitemid 23044831)
26. Clark CA, Spitzer KA, Nadler JN, Laskin CA. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol 2003;30:2127-32. (Pubitemid 37221840)
27. Ginsberg JS, Brill-Edwards P, Johnston M, Denburg JA, Andrew M, Burrows RF, et al. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood 1992;80:975-80.
28. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11. (Pubitemid 30265586)
29. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
30. Royal College of Obstetricians and Gynaecologists (RCOG). The investigation and treatment of couples with recurrent miscarriage. London (UK): Royal College of Obstetricians and Gynaecologists; 2003. p. 13. URL: http://www.guideline.gov/browse/archive.aspx?type-2.
31. American College of Obstetricians and Gynecologists. Antiphospholipid syndrome guidelines. 2005. URL: http://www.guideline.gov/summary/summary.aspx? doc-id-10928&nbr-005708&string-antiphospholipid.
32. Finnish Medical Society. Evidence based guidelines for systemic disease in pregnancy. 2006. URL: http://www.guideline.gov/content.aspx?id-11046.
33. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992;80:614-20.
34. Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985;313:1322-6. (Pubitemid 16206021)
35. Tan LK, Tan HK, Lee CT, Tan ASA. Outcome of pregnancy in Asian women with systemic lupus erythematosus: experience of a single perinatal centre in Singapore. Ann Acad Med Singapore 2002;31:290-5.
36. Amigo MC, Khamashta MA, Hughes GR. Antiphospholipid syndrome in SLE. Baillieres Clin Rheumatol 1998;12:477-93. (Pubitemid 28488244)
37. Petri M, Allbritton J. Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort. J Rheumatol 1993;20:650-6. (Pubitemid 23138853)
38. Welsch S, Branch DW. Antiphospholipid syndrome in pregnancy: obstetric concerns and treatment. Rheum Dis Clin North Am 1997;23:71-84. (Pubitemid 27089256)
39. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006;295:1050-7.
40. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005;2: CD002859.
41. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002;100:408-13. (Pubitemid 35246124)
42. Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 2005;83:684-90. (Pubitemid 40348581)
43. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584-9. (Pubitemid 26165282)
44. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314: 253-7. (Pubitemid 27047378)
45. Malinowski A, Dynski MA, Maciolek-Blewniewska G, Glowacka E, Pawlowski T, Babula G. Treatment outcome in women suffering from recurrent miscarriages and antiphospholipid syndrome. Ginekol Pol 2003;74:1213-22. In Polish.
46. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000;183:1008-12.
47. Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006;54:3640-7. (Pubitemid 44737176)
48. Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996;14: 131-6. (Pubitemid 26156755)
49. Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DL, Sebbough D, Wechsler B, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003;48:3207-11. (Pubitemid 37409333)
50. Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, Koren G. Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res B Dev Reprod Toxicol 2003;68:70-84. (Pubitemid 37248105)
51. Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JL, Tura BR, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001;10: 401-4. (Pubitemid 32578614)
52. Buyon J, Roubey R, Swersky S, Pompeo L, Parke A, Baxi L, et al. Complete congenital heart block: risk of occurrence and therapeutic approach to prevention. J Rheumatol 1988;15: 1104-8.
53. Ramsey-Goldman R, Kutzer JE, Kuller LH, Guzick D, Carpenter AB, Medsger TA Jr. Pregnancy outcome and anti-cardiolipin antibody in women with systemic lupus erythematosus. Am J Epidemiol 1993;138:1057-69. (Pubitemid 24018123)
54. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003;124:9-17. (Pubitemid 36055333)
55. Muirhead N, Sabharwal AR, Rieder MJ, Lazarovits AI, Hollomby DJ. The outcome of pregnancy following renal transplantation: the experience of a single center. Transplantation 1992;54:429-32.
56. Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 2006;15:546-54. (Pubitemid 44336269)
57. Schwarz EB, Maselli J, Norton M, Gonzales R. Prescription of teratogenic medications in United States ambulatory practices. Am J Med 2005;118:1240-9. (Pubitemid 41566525)
58. Schwarz EB, Postlethwaite DA, Hung YY, Armstrong M.A. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductiveage women. Ann Intern Med 2007;147:370-6. (Pubitemid 351664537)
59. Wong CH, Chen TL, Lee CS, Lin CJ, Chen CP. Outcome of pregnancy in patients with systemic lupus erythematosus. Taiwan J Obstet Gynecol 2006;45:120-3.
60. Weisman CS, Maccannon DS, Henderson JT, Shortridge E, Orso CL. Contraceptive counseling in managed care: preventing unintended pregnancy in adults. Womens Health Issues 2002;12:79-95. (Pubitemid 34168526)
61. Buyon JP, Waltuck J, Kleinman C, Copel J. In utero identification and therapy of congenital heart block. Lupus 1995;4: 116-21.
62. Shinohara K, Miyagawa S, Fujita T, Aono T, Kidoguchi K. Neonatal lupus erythematosus: results of maternal corticosteroid therapy. Obstet Gynecol 1999;93:952-7. (Pubitemid 29247102)
63. Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the Research Registry for Neonatal Lupus. Arthritis Rheum 1999;42:2335-45. (Pubitemid 30333414)
64. Ramsey-Goldman R, Hom D, Deng JS, Ziegler GC, Kahl LE, Steen VD, et al. Anti-SS-A antibodies and fetal outcome in maternal systemic lupus erythematosus. Arthritis Rheum 1986;29:1269-73. (Pubitemid 16005518)
65. Watson RM, Braunstein BL, Watson AJ, Hochberg MC, Provost TT. Fetal wastage in women with anti-Ro(SSA) antibody. J Rheumatol 1986;13:90-4. (Pubitemid 16118730)
66. Leu LY, Lan JL. The influence on pregnancy of anti-SSA/Ro antibodies in systemic lupus erythematosus. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1992;25:12-20.
67. Mavragani CP, Dafni UG, Tzioufas AG, Moutsopoulos HM. Pregnancy outcome and anti-Ro/SSA in autoimmune diseases: a retrospective cohort study. Br J Rheumatol 1998; 37:740-5.
68. Johns KR, Morand EF, Littlejohn GO. Pregnancy outcome in systemic lupus erythematosus (SLE): a review of 54 cases. Aust N Z J Med 1998;28:18-22. (Pubitemid 28131487)
69. Loizou S, Byron MA, Englert HJ, David J, Hughes GR, Walport MJ. Association of quantitative anticardiolipin antibody levels with fetal loss and time of loss in systemic lupus erythematosus. Q J Med 1988;68:525-31.
70. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992;166:1318-23.
71. Silver RK, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG, Ragin A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibodypositive obstetric patients. Am J Obstet Gynecol 1993;169: 1411-7. (Pubitemid 24009170)
72. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584-9. (Pubitemid 26165282)
73. Tulppala M, Marttunen M, Soderstrom-Anttila V, Foudila T, Ailus K, Palosuo T, et al. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum Reprod 1997;12:1567-72. (Pubitemid 27373218)
74. Cowchock S, Reece EA, and the Organizing Group of the Antiphospholipid Antibody Treatment Trial. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Am J Obstet Gynecol 1997;176:1099-100. (Pubitemid 27227526)
75. Laskin CA, Bombardier C, Hannah ME, Mandel FP, Ritchie Pregnancy and Reproductive Health QIs in SLE 29 JW, Farewell V, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997;337:148-53. (Pubitemid 27306285)
76. Branch DW, Peaceman AM, Druzin M, Silver RK, El-Sayed Y, Silver RM, et al, and The Pregnancy Loss Study Group. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol 2000;182: 122-7. (Pubitemid 30074379)
77. Vaquero E, Lazzarin N, Valensise H, Menghini S, Di Pierro G, Cesa F, et al. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin. Am J Reprod Immunol 2001; 45:174-9. (Pubitemid 32156569)
78. Triolo G, Ferrante A, Ciccia F, Accardo-Palumbo A, Perino A, Castelli A, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003;48:728-31. (Pubitemid 36302009)
79. Stephenson MD, Ballem PJ, Tsang P, Purkiss S, Ensworth S, Houlihan E, et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004;26:729-34.